Company intelligence / Profile preview
Cytogel Pharma
Darien, Connecticut, United Statescytogelpharma.com ↗
- Ownership
- Private
- Development stage
- Phase 2
01
Overview
CYT‑1010, an endomorphin peptide therapy, has demonstrated safety and analgesic activity in Phase 1 human studies. It showed effective pain relief with minimal addiction potential or respiratory depression in preclinical models. The compound is now advancing into Phase 2 trials as a first-in-class alternative to traditional opioids.
- Therapeutic areas
- ImmunologyNeurology
- Modalities
- Peptides (endomorphin family)Drug delivery technologies (hydrogels)
- Industry
- Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
Beyond the preview
Go deeper on Cytogel Pharma.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Cytogel Pharma.